Details

Autor(en) / Beteiligte

• Baldari, S.
• Ferraù, F.
• Alafaci, C.
• Herberg, A.
• Granata, F.
• Militano, V.
• Salpietro, F. M.
• Trimarchi, F.
• Cannavò, S.

Titel

First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment

Ist Teil von

• Pituitary, 2012-12, Vol.15 (Suppl 1), p.57-60

Ort / Verlag

Boston: Springer US

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• In prolactin-secreting giant adenomas, cabergoline treatment is the first line approach. Surgery and/or radiotherapy are indicated when the tumour is resistant to medical treatment and continues growing, causing visual field impairment. Data concerning other therapeutic approach are scanty. Although PRL-secreting tumours may express somatostatin receptors type 2, 3 and 5, somatostatin analogs treatment is generally ineffective and peptide receptor radionuclide therapy (PRRT) has never been reported. A 58 year-old woman complaining of severe neurological symptoms caused by a giant prolactinoma, relapsing after surgery and not-responding to dopamine-agonists and octreotide LAR treatment, underwent four cycles of PRRT with 111-Indium-DTPA-octreotide with remarkable tumour shrinkage and a significant improvement in clinical conditions. No side effects were reported. This is the first report on the effectiveness and safety of PRRT with radio-labelled somatostatin analogs in a patient with aggressive giant prolactinoma resistant to conventional treatment.